title: Incidence and mortality of hip fractures in the United States.
abstract: BACKGROUND
  Understanding the incidence and subsequent mortality following hip fracture is essential to measuring population health and the value of improvements in health care.
  
  
  OBJECTIVE
  To examine trends in hip fracture incidence and resulting mortality over 20 years in the US Medicare population.
  
  
  METHODS
  Observational study using data from a 20% sample of Medicare claims from 1985-2005. In patients 65 years or older, we identified 786,717 hip fractures for analysis. Medication data were obtained from 109,805 respondents to the Medicare Current Beneficiary Survey between 1992 and 2005.
  
  
  METHODS
  Age- and sex-specific incidence of hip fracture and age- and risk-adjusted mortality rates.
  
  
  RESULTS
  Between 1986 and 2005, the annual mean number of hip fractures was 957.3 per 100,000 (95% confidence interval [CI], 921.7-992.9) for women and 414.4 per 100,000 (95% CI, 401.6-427.3) for men. The age-adjusted incidence of hip fracture increased from 1986 to 1995 and then steadily declined from 1995 to 2005. In women, incidence increased 9.0%, from 964.2 per 100,000 (95% CI, 958.3-970.1) in 1986 to 1050.9 (95% CI, 1045.2-1056.7) in 1995, with a subsequent decline of 24.5% to 793.5 (95% CI, 788.7-798.3) in 2005. In men, the increase in incidence from 1986 to 1995 was 16.4%, from 392.4 (95% CI, 387.8-397.0) to 456.6 (95% CI, 452.0-461.3), and the subsequent decrease to 2005 was 19.2%, to 369.0 (95% CI, 365.1-372.8). Age- and risk-adjusted mortality in women declined by 11.9%, 14.9%, and 8.8% for 30-, 180-, and 360-day mortality, respectively. For men, age- and risk-adjusted mortality decreased by 21.8%, 25.4%, and 20.0% for 30-, 180-, and 360-day mortality, respectively. Over time, patients with hip fracture have had an increase in all comorbidities recorded except paralysis. The incidence decrease is coincident with increased use of bisphosphonates.
  
  
  CONCLUSIONS
  In the United States, hip fracture rates and subsequent mortality among persons 65 years and older are declining, and comorbidities among patients with hip fractures have increased.
authors.affiliation: Division of Orthopedic Surgery, University of Calgary, Alberta Children's Hospital, 2888 Shaganappi Trail NW, Calgary, AB, Canada T3B 6A8. carmen.brauer@albertahealthservices.ca
authors.forename: Carmen A
authors.initials: CA
authors.lastname: Brauer
authors.forename: Marcelo
authors.initials: M
authors.lastname: Coca-Perraillon
authors.forename: David M
authors.initials: DM
authors.lastname: Cutler
authors.forename: Allison B
authors.initials: AB
authors.lastname: Rosen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D015897:Comorbidity; D004164:Diphosphonates / Q000627:therapeutic use; D004363:Drug Utilization; D015914:Estrogen Replacement Therapy / Q000706:statistics & numerical data; D005260:Female; D006620:Hip Fractures / Q000453:epidemiology* / Q000401:mortality; D006801:Humans; D015994:Incidence; D008297:Male; D006278:Medicare; D019370:Observation; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators